Eye drops containing a synthetic peptide designed from spider venom eliminated resistant S. aureus eye infections in rabbits, destroyed 90% of bacterial biofilms, and showed no eye toxicity.
90% biofilm destructionThe spider venom peptide LyeTxI-b reduced bacterial biofilm viability by 90% — a critical capability since biofilm-protected bacteria are the main reason many corneal infections resist standard antibiotic treatment.
What the researchers found
Eye drops containing LyeTxI-b — a synthetic antimicrobial peptide designed from a Brazilian wolf spider (Lycosa erithrognatha) venom toxin — effectively treated resistant bacterial keratitis in rabbits with no signs of ocular toxicity. The peptide killed planktonic Staphylococcus aureus bacteria at a very low concentration (MIC 3.6 μmol/L), reduced biofilm viability by 90%, and when applied as drops four times daily for one week, eliminated bacteria and reduced inflammatory cell activity to levels comparable to healthy untreated eyes. Toxicity testing on chorioallantoic membranes and the standard Draize eye irritation test showed no adverse effects.
Why it matters
Bacterial keratitis (corneal infection) can cause rapid, severe vision loss and is a leading cause of corneal blindness worldwide. Antibiotic-resistant strains of Staphylococcus aureus are increasingly common, and bacteria protected within biofilms on the corneal surface are notoriously difficult to treat. Spider venom-derived peptides offer a fundamentally different antimicrobial mechanism than conventional antibiotics — they typically disrupt bacterial membranes, making resistance development much harder. The added anti-inflammatory activity of LyeTxI-b addresses both the infection and the damaging immune response.
The numbers in context
MIC 3.6 μmol/L · 90% biofilm viability reduction · 4 drops/day for 7 days · 4 × 10⁵ S. aureus cells for infection induction · No ocular toxicity
How the study worked
Researchers induced bacterial keratitis in New Zealand white rabbits by intrastromal injection of S. aureus (4 × 10⁵ cells). The peptide eye drop formulation (LyeTxI-b 28.9 μmol/L in 0.5% CMC and 0.9% NaCl) was instilled four times daily for one week. Outcomes included slit-lamp biomicroscopy, corneal histopathology, and quantification of inflammatory cell infiltration through myeloperoxidase (MPO) and N-acetylglucosaminidase (NAG) assays. Ocular safety was assessed via chorioallantoic membrane and Draize tests. In vitro MIC and biofilm viability assays were also performed.
Who was studied
New Zealand white rabbits with experimentally induced S. aureus keratitis, plus in vitro bacterial assays
What this study cannot tell us
This is a rabbit model — ocular pharmacokinetics and immune responses differ between rabbits and humans. The study tested only S. aureus, so efficacy against other keratitis pathogens (Pseudomonas, fungi) is unknown. Sample sizes for the animal experiments are not specified in the abstract. The one-week treatment duration doesn't address whether longer courses would be needed for more severe infections. Manufacturing, stability, and cost considerations for a clinical formulation are not discussed.
How to read the evidence
This is a preclinical animal study with well-controlled experimental design and both in vitro and in vivo components. The rabbit keratitis model is a standard, well-validated model for ophthalmic drug development. However, no human studies have been conducted, and the sample sizes are not specified.
When this study was published
Published in 2019, this study demonstrates a viable preclinical candidate for antimicrobial peptide eye drops. The increasing prevalence of antibiotic-resistant eye infections makes this work more relevant than ever, though clinical development status is unknown.
The bigger picture
Antibiotic resistance is a growing crisis in ophthalmology, with resistant corneal infections increasingly difficult to treat. Antimicrobial peptides derived from venoms represent one of nature's oldest defense systems against infection and offer mechanisms of action that bacteria struggle to develop resistance against. The fact that LyeTxI-b also reduces inflammation is a significant bonus — most antibiotics treat the infection but do nothing for the inflammatory damage that often causes the actual vision loss. Spider venom peptides join a growing pipeline of venom-derived therapeutics in ophthalmology.
Questions still open
- Would LyeTxI-b eye drops be effective against other common keratitis pathogens, particularly Pseudomonas aeruginosa and fungal organisms?
- Can the peptide formulation be stabilized for commercial shelf life, and what would the manufacturing cost be compared to conventional antibiotics?
- Is the peptide's anti-inflammatory mechanism direct or secondary to bacterial clearance?
Common questions
How does a spider venom peptide kill bacteria?
Is it safe to put spider venom in your eyes?
Read the original research
A New Topical Eye Drop Containing LyeTxI-b, A Synthetic Peptide Designed from A Lycosa erithrognata Venom Toxin, Was Effective to Treat Resistant Bacterial Keratitis.
Toxins, 11(4)
Citation
Silva, Carolina Nunes da; Silva, Flavia Rodrigues da; Dourado, Lays Fernanda Nunes; Reis, Pablo Victor Mendes Dos; Silva, Rummenigge Oliveira; Costa, Bruna Lopes da; Nunes, Paula Santos; Amaral, Flávio Almeida; Santos, Vera Lúcia Dos; de Lima, Maria Elena; Silva Cunha Júnior, Armando da. (2019). A New Topical Eye Drop Containing LyeTxI-b, A Synthetic Peptide Designed from A Lycosa erithrognata Venom Toxin, Was Effective to Treat Resistant Bacterial Keratitis.. Toxins, 11(4). https://doi.org/10.3390/toxins11040203